Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

Wei Wei, Young Shik Shin, Min Xue, Tomoo Matsutani, Kenta Masui, Huijun Yang, Shiro Ikegami, Yuchao Gu, Ken Herrmann, Dazy Johnson, Xiangming Ding, Kiwook Hwang, Jungwoo Kim, Jian Zhou, Yapeng Su, Xinmin Li, Bruno Bonetti, Rajesh Chopra, C. David James, Webster K. CaveneeTimothy F. Cloughesy, Paul S. Mischel*, James R. Heath, Beatrice Gini

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

91 Scopus citations

Abstract

Intratumoral heterogeneity of signaling networks may contribute to targeted cancer therapy resistance, including in the highly lethal brain cancer glioblastoma (GBM). We performed single-cell phosphoproteomics on a patient-derived in vivo GBM model of mTOR kinase inhibitor resistance and coupled it to an analytical approach for detecting changes in signaling coordination. Alterations in the protein signaling coordination were resolved as early as 2.5 days after treatment, anticipating drug resistance long before it was clinically manifest. Combination therapies were identified that resulted in complete and sustained tumor suppression in vivo. This approach may identify actionable alterations in signal coordination that underlie adaptive resistance, which can be suppressed through combination drug therapy, including non-obvious drug combinations.

Original languageEnglish (US)
Pages (from-to)563-573
Number of pages11
JournalCancer Cell
Volume29
Issue number4
DOIs
StatePublished - Apr 11 2016

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma'. Together they form a unique fingerprint.

Cite this